MCID: KHN001
MIFTS: 40

Kuhnt-Junius Degeneration

Categories: Eye diseases

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 12 15
Susceptibility to Neovascular Type of Age-Related Macular Degeneration 6
Exudative Senile Macular Degeneration of Retina 12
Neovascular Age-Related Macular Degeneration 12
Exudative Age-Related Macular Degeneration 73
Wet Senile Macular Retinal Degeneration 12
Senile Macular Degeneration, Wet 12
Exudative Macular Degeneration 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10873
ICD10 33 H35.32
ICD9CM 35 362.52

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary : Kuhnt-Junius Degeneration, also known as susceptibility to neovascular type of age-related macular degeneration, is related to macular degeneration, age-related, 1 and central serous chorioretinopathy. An important gene associated with Kuhnt-Junius Degeneration is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Focal Adhesion. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and vision/eye

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 macular degeneration, age-related, 1 24.0 ARMS2 CFB CFH CFHR4 HTRA1 KDR
2 central serous chorioretinopathy 10.6 ARMS2 CFH
3 yemenite deaf-blind hypopigmentation syndrome 10.5 CFH VEGFA
4 dense deposit disease 10.3 CFB CFH
5 hemolytic uremic syndrome, atypical 1 10.3 CFH CFHR4
6 angiokeratoma circumscriptum 10.3 KDR VEGFA
7 enterocolitis 10.3 CFB CFH
8 capillary hemangioma 10.3 KDR VEGFA
9 skin hemangioma 10.2 KDR VEGFA
10 radiation proctitis 10.2 KDR VEGFA
11 acute hemorrhagic leukoencephalitis 10.2 KDR VEGFA
12 angiomatous meningioma 10.1 KDR VEGFA
13 leukostasis 10.1 KDR VEGFA
14 lymphangioma 10.1 KDR VEGFA
15 retinal drusen 10.0 ARMS2 CFB CFH
16 coats disease 10.0 KDR VEGFA
17 neovascular glaucoma 10.0 PGF VEGFA
18 retinal disease 10.0 ARMS2 CFB CFH
19 vascular cancer 10.0 KDR VEGFA
20 cancer-associated retinopathy 10.0 PGF VEGFA
21 retinal vascular occlusion 9.9 PGF VEGFA
22 epileptic encephalopathy, childhood-onset 9.9 KDR VEGFA
23 membranoproliferative glomerulonephritis 9.9 CFB CFH
24 hemolytic-uremic syndrome 9.8 CFB CFH CFHR4
25 arteriovenous malformations of the brain 9.7 KDR VEGFA
26 multifocal choroiditis 9.7 ARMS2 CFB CFH HTRA1
27 choroiditis 9.7 ARMS2 CFB CFH HTRA1
28 breast carcinoma in situ 9.5 KDR VEGFA
29 epithelioid hemangioendothelioma 9.3 KDR PGF VEGFA
30 limb ischemia 9.3 KDR PGF VEGFA
31 placental insufficiency 9.3 KDR PGF VEGFA
32 microvascular complications of diabetes 5 9.3 KDR PGF VEGFA
33 degeneration of macula and posterior pole 8.2 ARMS2 CFB CFH HTRA1 KDR SKIV2L

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 CFH HTRA1 KDR PGF VEGFA VEGFB
2 vision/eye MP:0005391 9.17 CFH HTRA1 KDR PGF VEGFA VEGFB

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 347396-82-1 459903
3
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
4
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
6
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
7
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
8
Menthol Approved Phase 4 2216-51-5 16666
9
Lactitol Investigational Phase 4 585-86-4 3871
10 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Antibodies Phase 4,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 4,Phase 2,Phase 1
16 Immunoglobulins Phase 4,Phase 2,Phase 1
17 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Respiratory System Agents Phase 4,Phase 2,Not Applicable
21 Autoantibodies Phase 4
22 Analgesics Phase 4,Phase 2,Not Applicable
23 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
25 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Not Applicable
26 Autonomic Agents Phase 4,Phase 2,Phase 1
27 Cyclooxygenase Inhibitors Phase 4
28 Ketorolac Tromethamine Phase 4
29 Nasal Decongestants Phase 4,Phase 2
30 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Tetrahydrozoline Phase 4,Phase 2,Phase 3,Phase 1
34 Vasoconstrictor Agents Phase 4,Phase 2,Not Applicable
35 Pyranoprofen Phase 4
36 Tocolytic Agents Phase 4
37 Omega 3 Fatty Acid Nutraceutical Phase 4,Not Applicable
38
Triamcinolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
39
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
40
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 3154 5284549
41
Timolol Approved Phase 2, Phase 3 26839-75-8 33624 5478
42
Iodine Approved, Investigational Phase 3 7553-56-2 807
43
Povidone Approved Phase 3 9003-39-8
44
Povidone-iodine Approved Phase 3 25655-41-8
45 Anecortave Investigational Phase 3,Phase 2,Phase 1 10184-70-0
46
Squalamine Investigational Phase 3,Phase 2 148717-90-2
47 Fibrinolytic Agents Phase 2, Phase 3
48 Plasminogen Phase 2, Phase 3
49 Tissue Plasminogen Activator Phase 2, Phase 3
50 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
2 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Unknown status NCT01896284 Phase 4 0.5mg aflibercept
3 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Unknown status NCT02681783 Phase 4 aflibercept
4 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
5 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
6 Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Unknown status NCT01961414 Phase 4 Aflibercept
7 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
8 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
9 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Unknown status NCT02689518 Phase 4 Intravitreal aflibercept injection
10 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
11 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) Completed NCT01988662 Phase 4
12 Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration Completed NCT02843490 Phase 4 Ranibizumab
13 Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
14 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept Completed NCT02125864 Phase 4 Aflibercept
15 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START Completed NCT02246829 Phase 4
16 Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
17 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed NCT02161575 Phase 4 Ranibizumab
18 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4 Ranibizumab
19 Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Completed NCT02944227 Phase 4 Lucentis
20 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
21 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
22 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
23 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
24 Single or Combined Protocols for NV-AMD Completed NCT03552770 Phase 4 Bevacizumab
25 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
26 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
27 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
28 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4 Eylea
29 Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Completed NCT02257632 Phase 4 Ranibizumab;Aflibercept
30 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
31 Ranibizumab Plus Indomethacin Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
32 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
33 Study EvAluating Genotypes While Using Lucentis 2 Completed NCT01464723 Phase 4 Ranibizumab
34 Head to Head Study of Anti-VEGF Treatment. Completed NCT02577107 Phase 4 ranibizumab;Conbercept
35 Study for Recalcitrant Age Related Macular Degeneration Completed NCT01543568 Phase 4 aflibercept 2.0 mg
36 A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) Completed NCT01542866 Phase 4
37 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
38 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. Recruiting NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
39 Intravitreal Vascular Endothelial Growth Factor Trap-eye for Submacular Hemorrhage Recruiting NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
40 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye Active, not recruiting NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
41 Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD Active, not recruiting NCT01213667 Phase 4 Ranibizumab
42 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Not yet recruiting NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
43 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
44 A Study Comparing Efficacy and Safety of "Treat-and-Extend" Regimen Versus PRN of Conbercept in AMD Not yet recruiting NCT02802657 Phase 4 Conbercept
45 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Not yet recruiting NCT02976194 Phase 4 ranibizumab
46 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
47 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
48 A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) Terminated NCT00312351 Phase 4 Pegaptanib sodium
49 Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Terminated NCT00134667 Phase 4 Photodynamic Therapy (PDT) with Visudyne (verteporfin);Macugen (pegaptanib sodium)
50 TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Terminated NCT01983579 Phase 4

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

MalaCards organs/tissues related to Kuhnt-Junius Degeneration:

41
Eye, Endothelial, Retina, Testes

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

# Title Authors Year
1
Senile macular degeneration and Kuhnt-Junius degeneration as separate entities: review. ( 3878471 )
1985

Variations for Kuhnt-Junius Degeneration

ClinVar genetic disease variations for Kuhnt-Junius Degeneration:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh37 Chromosome 10, 124220544: 124220544
2 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh38 Chromosome 10, 122461028: 122461028

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

Pathways related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 KDR PGF VEGFA VEGFB
2
Show member pathways
12.56 KDR PGF VEGFA VEGFB
3 12.37 KDR PGF VEGFA VEGFB
4
Show member pathways
12.31 KDR PGF VEGFA VEGFB
5
Show member pathways
12.09 KDR VEGFA VEGFB
6
Show member pathways
12 KDR PGF VEGFA VEGFB
7
Show member pathways
11.89 KDR VEGFA VEGFB
8
Show member pathways
11.22 KDR PGF VEGFA VEGFB
9
Show member pathways
11.13 KDR VEGFA
10 11.01 KDR VEGFA
11 10.96 KDR VEGFA VEGFB
12 10.81 KDR VEGFA
13 10.21 VEGFA VEGFB
14
Show member pathways
10.13 KDR PGF VEGFA VEGFB

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CFB CFH HTRA1 PGF VEGFA VEGFB
2 extracellular region GO:0005576 9.23 CFB CFH CFHR4 HTRA1 KDR PGF

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.73 KDR PGF VEGFA VEGFB
2 response to hypoxia GO:0001666 9.72 PGF VEGFA VEGFB
3 regulation of cell shape GO:0008360 9.7 KDR SHROOM3 VEGFA
4 regulation of complement activation GO:0030449 9.67 CFB CFH CFHR4
5 positive regulation of angiogenesis GO:0045766 9.62 KDR PGF VEGFA VEGFB
6 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.57 KDR VEGFA
7 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.56 KDR VEGFA
8 positive regulation of focal adhesion assembly GO:0051894 9.54 KDR VEGFA
9 positive regulation of cell division GO:0051781 9.54 PGF VEGFA VEGFB
10 cell migration involved in sprouting angiogenesis GO:0002042 9.51 KDR VEGFA
11 complement activation, alternative pathway GO:0006957 9.48 CFB CFH
12 positive regulation of positive chemotaxis GO:0050927 9.46 KDR VEGFA
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.46 KDR PGF VEGFA VEGFB
14 induction of positive chemotaxis GO:0050930 9.43 PGF VEGFA VEGFB
15 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.4 KDR VEGFA
16 positive regulation of endothelial cell proliferation GO:0001938 9.26 KDR PGF VEGFA VEGFB
17 positive regulation of mast cell chemotaxis GO:0060754 8.8 PGF VEGFA VEGFB

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 PGF VEGFA VEGFB
2 vascular endothelial growth factor receptor 2 binding GO:0043184 9.26 VEGFA VEGFB
3 heparin binding GO:0008201 9.26 CFH PGF VEGFA VEGFB
4 vascular endothelial growth factor receptor binding GO:0005172 9.16 PGF VEGFA
5 vascular endothelial growth factor receptor 1 binding GO:0043183 8.62 VEGFA VEGFB

Sources for Kuhnt-Junius Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....